What roles do elevated levels of matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and decreased levels of interleukin (IL)-33 play in the development and progression of myocardial infarction, with a specific focus on how decreased IL-33 levels contribute to plaque rupture and acute coronary syndrome?